<DOC>
	<DOCNO>NCT02753400</DOCNO>
	<brief_summary>To evaluate effect oral emixustat hydrochloride ( emixustat ) aqueous humor biomarkers associate proliferative diabetic retinopathy ( PDR ) baseline week 12 .</brief_summary>
	<brief_title>Study Evaluate Effects Emixustat Hydrochloride Subjects With Proliferative Diabetic Retinopathy</brief_title>
	<detailed_description>This multicenter , randomize , double-masked , placebo-controlled study evaluate effect emixustat subject PDR . Subjects randomly assign either emixustat placebo arm treat daily ( QD ) 12 week . Doses emixustat doubled weekly basis week 4 subject hold stable dose remainder 12-week dosing regimen . Subjects placebo group mock-titrated schedule emixustat arm .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<criteria>Able willing provide write informed consent Documented diagnosis type 1 type 2 diabetes mellitus Meets specific ocular criterion study eye include limited , presence PDR without diabetic macular edema study eye treatment defer least 4 week Day 1 visit Media clarity , pupillary dilation , subject cooperation sufficient obtain adequate assessment Any condition would preclude participation study ( e.g. , unstable medical status include blood pressure , cardiovascular disease glycemic control ) History myocardial infarction acute cardiac event History chronic renal failure require dialysis kidney transplant Prior participation clinical study emixustat Treatment investigational study drug within 30 day screen Known allergy fluorescein sodium injection angiography Treatment specific prohibit medication therapy begin 4 week prior screen throughout duration study History systemic antiVEGF proVEGF treatment within 4 month prior randomization Prespecified laboratory abnormality screen Specific ocular characteristic study eye Male subject surgically sterile willing practice medically accept method birth control female partner childbearing potential screen 30 day follow completion study Female subject childbearing potential willing practice medically accept method birth control nonsurgically sterile male sexual partner screen 30 day follow completion study Female subject pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>